ECT’s MXene runs open a path to US defence customers

ECT moves MXene programme from concept to physical product

Environmental Clean Technologies Limited (ASX:ECT) says its Flash Joule Heating programme has produced MXene in two initial synthesis runs, an early technical milestone for the company’s proposed US defence and advanced-materials business. MXene formation was confirmed through in-house scanning electron microscopy and X-ray diffraction, alongside third-party XRD testing.

The results remain preliminary. Each run used 400 grams of MAX phase feedstock plus carbon filler, ran for between 30 and 60 minutes, and produced a peak reported yield of 31%. ECT said the testing showed aluminium was preferentially removed while titanium was retained, with the layer spacing matching chlorine-terminated MXene. The company also identified a pathway to increase conversion.

Repeatability is the next test for the FJH process

The announcement is meaningful because it addresses the first question in ECT’s commercial sequence: can the process form MXene? It does not yet answer whether the material can be made repeatedly, at scale, to customer specifications or at commercially attractive economics.

ECT is pursuing an acid-free production route licensed from Rice University’s Tour Lab, using electrical pulses to generate extreme heat in seconds. The presentation contrasts that process with conventional hydrofluoric-acid etching, which it says can take roughly 48 to 72 hours. Its stated target is eventual production of about one kilogram per day at Metallium’s Gator Point facility in Texas, but the company stressed that target production rates remain subject to optimisation and repeatability testing.

The commercial pathway also depends on the defence-use sublicence previously secured by Xenica Inc from MXene Inc. That licence provides military end-use rights, but ECT reiterated that it is not a customer contract and that the company has no contracted defence sales. Customer samples, independent testing and specification qualification are the next steps before any supply agreement can emerge.

Shareholder approval remains central to the funding and acquisition plan

The proposed acquisition of Xenica Materials and the second tranche of ECT’s placement both require shareholder approval at the extraordinary general meeting on 22 October. The presentation puts the second tranche at A$12 million and shows pro-forma cash of A$12.3 million after fees and the US$500,000 payment to Metallium for research and engineering support.

The capital supports a programme that is still moving through technical validation rather than commercial delivery. ECT’s presentation cites reference pricing above US$100 per gram for high-quality US-produced Ti₃C₂Tₓ powder, but expressly says that figure is not a forecast. Actual pricing would depend on grade, product form, volume, customer requirements and contracted terms.

PFAS remediation provides a second route for the same reactor platform

MXenes are the lead commercial story, but ECT is also advancing Rapid Electrothermal Mineralisation, or REM, for PFAS destruction. The company says laboratory testing achieved more than 99% removal of various PFAS in contaminated soils, with 96% to 99.9% of fluorine accounted for as inorganic fluoride on granular activated carbon and ion-exchange resins. Those results were achieved under controlled laboratory conditions and may not be replicated in the field.

ECT has submitted performance data to the US Environmental Protection Agency and is targeting a field demonstration in the first quarter of 2027 using a 22-kilowatt pilot system. That work could give the company a separate commercialisation path, although the field validation remains ahead and the earlier PFAS pilot system was described as targeting an in-field demonstration rather than representing completed commercial deployment.